MicroRNAs in the development of resistance to antiseizure drugs
and their potential as biomarkers in pharmacoresistant epilepsy

J 2021

MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy

BOHOŠOVÁ, Júlia, Jiří VAJČNER, Petr JABANDŽIEV, Hana OŠLEJŠKOVÁ, Ondřej SLABÝ et. al.

Základní údaje

Originální název

MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy

Autoři

BOHOŠOVÁ, Júlia (703 Slovensko, domácí), Jiří VAJČNER (203 Česká republika, domácí), Petr JABANDŽIEV (203 Česká republika, domácí), Hana OŠLEJŠKOVÁ (203 Česká republika, domácí), Ondřej SLABÝ (203 Česká republika, domácí) a Štefánia AULICKÁ (703 Slovensko, garant, domácí)

Vydání

Epilepsia, Hoboken, Wiley-Blackwell, 2021, 0013-9580

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.740

Kód RIV

RIV/00216224:14110/21:00120160

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1111/epi.17063

UT WoS

000692515800001

Klíčová slova anglicky

biomarkers; drug-resistant epilepsy; intractable epilepsy; noncoding RNA; refractory epilepsy

Štítky

14110317, 14110320, 14110513, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 2. 2022 07:22, Mgr. Tereza Miškechová

Anotace

V originále

Although many new antiseizure drugs have been developed in the past decade, approximately 30%-40% of patients remain pharmacoresistant. There are no clinical tools or guidelines for predicting therapeutic response in individual patients, leaving them no choice other than to try all antiseizure drugs available as they suffer debilitating seizures with no relief. The discovery of predictive biomarkers and early identification of pharmacoresistant patients is of the highest priority in this group. MicroRNAs (miRNAs), a class of short noncoding RNAs negatively regulating gene expression, have emerged in recent years in epilepsy, following a broader trend of their exploitation as biomarkers of various complex human diseases. We performed a systematic search of the PubMed database for original research articles focused on miRNA expression level profiling in patients with drug-resistant epilepsy or drug-resistant precilinical models and cell cultures. In this review, we summarize 17 publications concerning miRNAs as potential new biomarkers of resistance to antiseizure drugs and their potential role in the development of drug resistance or epilepsy. Although numerous knowledge gaps need to be filled and reviewed, and articles share some study design pitfalls, several miRNAs dysregulated in brain tissue and blood serum were identified independently by more than one paper. These results suggest a unique opportunity for disease monitoring and personalized therapeutic management in the future.

Návaznosti

NU21-04-00305, projekt VaV

Název: Analýza transkriptomu a metylace DNA u pacientů s fokální kortikální dysplázií

Investor: Ministerstvo zdravotnictví ČR, Analýza transkriptomu a metylace DNA u pacientů s fokální kortikální dysplázií, Podprogram 1 - standardní

Citovat

BOHOŠOVÁ, Júlia, Jiří VAJČNER, Petr JABANDŽIEV, Hana OŠLEJŠKOVÁ, Ondřej SLABÝ a Štefánia AULICKÁ. MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy. Epilepsia. Hoboken: Wiley-Blackwell, 2021, roč. 62, č. 11, s. 2573-2588. ISSN 0013-9580. Dostupné z: https://dx.doi.org/10.1111/epi.17063.

@article{1801101,
   author = {Bohošová, Júlia and Vajčner, Jiří and Jabandžiev, Petr and Ošlejšková, Hana and Slabý, Ondřej and Aulická, Štefánia},
   article_location = {Hoboken},
   article_number = {11},
   doi = {http://dx.doi.org/10.1111/epi.17063},
   keywords = {biomarkers; drug-resistant epilepsy; intractable epilepsy; noncoding RNA; refractory epilepsy},
   language = {eng},
   issn = {0013-9580},
   journal = {Epilepsia},
   title = {MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy},
   url = {https://onlinelibrary.wiley.com/doi/10.1111/epi.17063},
   volume = {62},
   year = {2021}
}

TY  - JOUR
ID  - 1801101
AU  - Bohošová, Júlia - Vajčner, Jiří - Jabandžiev, Petr - Ošlejšková, Hana - Slabý, Ondřej - Aulická, Štefánia
PY  - 2021
TI  - MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy
JF  - Epilepsia
VL  - 62
IS  - 11
SP  - 2573-2588
EP  - 2573-2588
PB  - Wiley-Blackwell
SN  - 00139580
KW  - biomarkers
KW  - drug-resistant epilepsy
KW  - intractable epilepsy
KW  - noncoding RNA
KW  - refractory epilepsy
UR  - https://onlinelibrary.wiley.com/doi/10.1111/epi.17063
N2  - Although many new antiseizure drugs have been developed in the past decade, approximately 30%-40% of patients remain pharmacoresistant. There are no clinical tools or guidelines for predicting therapeutic response in individual patients, leaving them no choice other than to try all antiseizure drugs available as they suffer debilitating seizures with no relief. The discovery of predictive biomarkers and early identification of pharmacoresistant patients is of the highest priority in this group. MicroRNAs (miRNAs), a class of short noncoding RNAs negatively regulating gene expression, have emerged in recent years in epilepsy, following a broader trend of their exploitation as biomarkers of various complex human diseases. We performed a systematic search of the PubMed database for original research articles focused on miRNA expression level profiling in patients with drug-resistant epilepsy or drug-resistant precilinical models and cell cultures. In this review, we summarize 17 publications concerning miRNAs as potential new biomarkers of resistance to antiseizure drugs and their potential role in the development of drug resistance or epilepsy. Although numerous knowledge gaps need to be filled and reviewed, and articles share some study design pitfalls, several miRNAs dysregulated in brain tissue and blood serum were identified independently by more than one paper. These results suggest a unique opportunity for disease monitoring and personalized therapeutic management in the future.
ER  -

BOHOŠOVÁ, Júlia, Jiří VAJČNER, Petr JABANDŽIEV, Hana OŠLEJŠKOVÁ, Ondřej SLABÝ a Štefánia AULICKÁ. MicroRNAs in the development of resistance to antiseizure drugs and their potential as biomarkers in pharmacoresistant epilepsy. \textit{Epilepsia}. Hoboken: Wiley-Blackwell, 2021, roč.~62, č.~11, s.~2573-2588. ISSN~0013-9580. Dostupné z: https://dx.doi.org/10.1111/epi.17063.

Podrobný výpis o publikaci